Protalix BioTherapeutics, Inc. 4
4 · Protalix BioTherapeutics, Inc. · Filed Aug 16, 2013
Insider Transaction Report
Form 4
Akirov Alfred
Director
Transactions
- Sale
Common Stock
2013-08-15$5.07/sh−2,330$11,813→ 4,915,383 total(indirect: By Corporation) - Sale
Common Stock
2013-08-14$5.05/sh−100,000$505,000→ 4,927,713 total(indirect: By Corporation) - Sale
Common Stock
2013-08-14$5.07/sh−5,000$25,350→ 4,922,713 total(indirect: By Corporation) - Sale
Common Stock
2013-08-14$5.08/sh−5,000$25,400→ 4,917,713 total(indirect: By Corporation)
Footnotes (1)
- [F1]All sales reported on this Form 4 were made by Alrov (Israel) Ltd.("Alrov Israel") and the column in Table 1 disclosing the amount of securities beneficially owned following the reported transactions includes 686,046 shares of the Issuer's common stock held by Technorov Holdings (1993) Ltd. ("Technorov"). Alrov Israel owns 100% of Al-Rov Technologies Holdings LTD, the holder of 80% of Technorov. The reporting person is the Chairman of Alrov Israel and the Chief Executive Officer of Technorov, and has the power to control their respective investment decisions. Alrov Israel is an Israeli publicly-traded company that is listed on the Tel Aviv Stock Exchange. The reporting person disclaims beneficial ownership of the securities of the Issuer held by Alrov Israel and Technorov, except to the extent of his proportional pecuniary interest therein.